Rexlemestrocel-L

Phase 3Cell therapy

MMesoblast, Ltd.

Rexlemestrocel-L is one of 66 small molecule programs targeting Low back pain. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Low Back PainActive, not recruiting

Heart FailureActive, not recruiting

Low Back PainPhase 3

Active, not recruiting

Heart FailurePhase 3

Active, not recruiting

Competition

Competitive Landscape

687 competitors in Heart Failure

#DrugCompanyPhaseTrials

Rexlemestrocel-L

MMesoblast, Ltd.

Phase 3

1 2

Amidate

Pfizer

Preclinical

1 3

Activase

Zemplar

Bystolic

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

4 6

Xifaxan

SSalix

Preclinical

2 7

Zoloft

VViatris Specialty LLC

Preclinical

2 8

Coumadin

AAbbott

Preclinical

1 9

Oraverse

LLife Extension Foundation Inc.

Preclinical

1 10

Statin

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Low Back Pain

NCT06325566

Clinical

Trials by Indication[1]

Low back pain2 trials

Placebo-controlled Study to Evaluate Rexlemestrocel-L Alone or Combined With Hyaluronic Acid in Participants With Chronic Low Back Pain

Completed·MMesoblast, Ltd.·Phase 3·NCT02412735·404 enrolled

Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain

Recruiting·MMesoblast, Ltd.·Phase 3·NCT06325566·300 enrolled

Heart Failure1 trial

Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure

Completed·MMesoblast, Ltd.·Phase 3·NCT02032004·565 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Rexlemestrocel-L. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Rexlemestrocel-L compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Rexlemestrocel-L. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mesoblast, Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 3[1]
Company: MMesoblast, Ltd.

Rexlemestrocel-L

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Low back pain2 trials

Heart Failure1 trial

References

Drug Info

Quick Facts

Related News